The ability of pH-sensitive liposomes and immunoliposomes to deliver synthetic antisense oligonucleotides (oligos) into human myeloid and lymphoid leukaemia cells was examined. The cellular uptake of an 18mer anti-myb oligonucleotide encapsulated in liposomes was from three- to five-fold higher than that of 32P-oligos alone. In addition, anti-CD32 or anti-CD2 immunoliposomes improved the delivery of oligos to leukaemic cells carrying the appropriate receptor for the specific antibody-linked immunoliposome. The uptake of oligos was twice that of the liposome or non-specific immunoliposome encapsulated oligos. These findings support the use of liposomes or immunoliposomes to deliver antisense oligos into human leukaemic cells.